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In the literature, CO monitoring has been approached in different but complimentary knowledge domains. These concern (i) 
technical issues (what is really measured and how is CO calculated ?; are the measurements continuous versus discontinuous ?); 
(ii) invasiveness, which according to the definition of this term can classify different CO monitors as invasive, minimally invasive 
or non invasive; it is worth mentioning that it is not because a monitor is considered as non invasive that it can be used under all 
clinical circumstances; for instance, transoesophageal doppler monitors are considered as non invasive but their use in awake, non 
intubated patients is nearly impossible; (iii) diagnostic performance as compared to a gold standard or reference technique; most 
of the literature on comparisons of CO monitors has been dedicated to diagnostic performance; (iv) changes in medical practice 
based on information provided by each type of CO monitors; (v) changes in outcome and resource utilization. 
In this presentation, in order to answer the question formulated in the title, I will discuss two issues: (i) comparisons of diagnostic 
performance with focus on the statistical tools 1-3, used for comparisons and the clinical relevance of these comparisons; with the 
statistical tools and adequate clinical reasoning we should be able to assert the interchangeability of different CO monitors (ii) the 
impact of CO monitoring on patient outcome and resource utilization ; I will analyse critically the available literature and attempt 
to explain why the use of CO monitors has not results in measurable changes in patient outcome. 4 5-8. 9. 
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Among the recent advances in the management of intra-abdominal sepsis are the use of two biomarkers of inflammation, C-
reactive protein (CRP) and procalcitonin (PCT). Both biomarkers were investigated for their potential use for diagnosis, prognosis 
and therapy guidance 1-3. Any use of these two biomarkers must be based on a detailed understanding of their biology. The goals of 
the presentation are to review: (i) the biology of CRP and PCT; (ii) the diagnosis and prognosis performances of the two biomarkers 
in bacterial (including intra-abdominal) sepsis; (iii) the potential use of these biomarkers to guide therapy. 
C-reactive protein (CRP), named for its capacity to precipitate the somatic C-polysaccharide of Streptococcus pneumoniae, 
was discovered in 1930 (see for a review 4 and is a major component of the acute phase reaction (APR). In healthy young adults, 
the median concentration of CRP is 0.8 mg/l, the 90th centile is 3.0 mg/l, and the 99th centile is 10 mg/l 5. Within 24 h after onset 
of inflammation, levels can increase as much as 1000-fold 5. Measurements of plasma CRP concentrations are routinely used in 
clinical practice to diagnose acute inflammation, follow up its response to therapy, diagnose infection in immuno-compromised 
host when other clinical signs are not sensitive. 
Procalcitonin (PCT) is a peptide barely detectable in healthy patients but its concentration can be increased several thousand 
fold in cases of inflammation secondary to bacterial and fungal infection but also to non-infectious causes 6-9. As a biomarker 
of inflammation/ bacterial and fungal infection, as comparable to other biomarkers such as C-reactive protein (CRP) 5, PCT is 
particular in that the significance in terms of outcome (beneificial, deleterious or neutral) of its increased concentrations is not 
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understood 6;7. For instance, high PCT values in neonates or patients with medullary carcinoma of the thyroid gland do not affect 
patient outcome 6; on the contrary, high PCT values are statistically associated with patient outcome in variety of clinical contexts 
characterized or not by bacterial or fungal infection 10;11.
The diagnostic and prognostic performances of PCT and CRP are probably not good enough to be used isolated from other 
clinical and laboratory information 12 . Nevertheless, accumulation of clinical experience and published reports is consistent with 
a very high negative predictive value of low PCT values 12. Low (< 0.25 µg/l) PCT values are consistent with absence of severe 
bacterial infection at least for some clinical contexts12. In addition, several clinical trials that still require confirmation with larger 
cohorts of patients, suggest that PCT could be used to guide the duration of antibiotic therapy is critically ill patients or in patients 
admitted to the emergency department 12-18. 
In summary, although it is too early to assert that information provided by serial PCT measurements could change clinical 
reasoning on initiation and duration of antibiotic treatment in critically ill patients, recent results suggest that this may be the 
case. 
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The development of our speciality has been fast, ever since the famous demonstration of ether anaesthesia by William TG 
Morton in 1846. We provide the sine qua non for the development of surgery. Although a lot of what we do is common, the 
development until today has taken varied courses throughout the world. We have one speciality, but the specialist training varies 
between 0 – 7 years. In some countries, physician anaesthesiologists do mainly anaesthetics, with or without helpers like nurses 
or technicians, but in others, we are also involved in intensive care medicine, emergency medicine and chronic pain treatment. 
Anaesthesiologists are also popular as managers and leaders. Our prestige and attractiveness by young colleagues also vary, 
sometimes leading to lack of manpower.
